Crosstalk among the proteome, lysine phosphorylation, and acetylation in romidepsin-treated colon cancer cells
Metrics: PDF 1418 views | HTML 1690 views | ?
Tian-Yun Wang1,2, Yu-Rong Chai3, Yan-Long Jia4, Jian-Hui Gao2, Xiao-Jun Peng5, Hua-Feng Han5
1Department of Biochemistry and Molecular Biology, Xinxiang Medical University, Henan, 453003, China
2Henan Collaborative Innovation Canter of Molecular Diagnosis and Laboratory Medicine, Xinxiang, Henan, 453003, China
3Department of Histology and Embryology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, 450001, China
4Pharmacy Collage, Xinxiang Medical University, Xinxiang, Henan, 453003, China
5Jingjie PTM BioLab (Hangzhou) Co. Ltd, Hangzhou, 310018, China
Tian-Yun Wang, email: email@example.com
Keywords: romidepsin, colon cancer, histone lysine-acetylation, proteome, histone lysine-phosphorylation
Received: November 13, 2015 Accepted: July 17, 2016 Published: July 26, 2016
Romidepsin (FK228) is one of the most promising histone-deacetylase inhibitors due to its potent antitumor activity, and has been used as a practical option for cancer therapy. However, FK228-induced changes in protein modifications and the crosstalk between different modifications has not been reported. To better understand the underlying mechanisms of FK228-related cancer therapy, we investigated the acetylome, phosphorylation, and crosstalk between modification datasets in colon cancer cells treated with FK228 by using stable-isotope labeling with amino acids in cell culture and affinity enrichment, followed by high-resolution liquid chromatography tandem mass spectrometry analysis. In total, 2728 protein groups, 1175 lysine-acetylation sites, and 4119 lysine-phosphorylation sites were quantified. When the quantification ratio thresholds were set to > 2.0 and < 0.5, respectively, a total of 115 and 38 lysine-acetylation sites in 85 and 32 proteins were quantified as increased and decreased targets, respectively, and 889 and 370 lysine-phosphorylation sites in 599 and 289 proteins were quantified as increased and decreased targets, respectively. Furthermore, we identified 274 proteins exhibiting both acetylation and phosphorylation modifications. These findings indicated possible involvement of these proteins in FK228-related treatment of colon cancer, and provided insight for further analysis of their biological function.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.